GUSTAVO MARTÍN VILLOLDO1, MARÍA TERESA POMBO2, MARIANA ARIS3, JOAQUÍN CHEMI1, PABLO MANDÓ3, SUPRIYA NAGARAJU4, JUAN CAMEAN1, ADRIÁN BURIONI1, DEBORAH EGEA1, MORA AMAT5, JOSÉ LEÓN MELLADO3, JOSÉ MORDOH3, ALBERTO VILLARONGA1, MARÍA MARCELA BARRIO3,*
Oncology Research, Vol.31, No.2, pp. 207-220, 2023, DOI:10.32604/or.2023.028163
- 10 April 2023
Abstract Intravesical Bacillus Calmette Guerin (BCG) is the gold standard therapy for intermediate/high-risk nonmuscle invasive bladder cancer (NMIBC). However, the response rate is ~60%, and 50% of non-responders will
progress to muscle-invasive disease. BCG induces massive local infiltration of inflammatory cells (Th1) and ultimately
cytotoxic tumor elimination. We searched for predictive biomarker of BCG response by analyzing tumor-infiltrating
lymphocyte (TIL) polarization in the tumor microenvironment (TME) in pre-treatment biopsies. Pre-treatment
biopsies from patients with NMIBC who received adequate intravesical instillation of BCG (n = 32) were evaluated
retrospectively by immunohistochemistry. TME polarization was assessed by quantifying… More >
Graphic Abstract
Login
Register
